Last updated: February 13, 2026
Overview
NDC 68992-3010 corresponds to Targretin (bexarotene) capsules, developed by Bayer. It is used primarily for cutaneous T-cell lymphoma (CTCL) and is approved for oral administration in multiple countries. The drug's market environment and pricing landscape are influenced by patent status, regulatory filings, competitor dynamics, and reimbursement policies.
Market Size and Demand Drivers
- Indications: The primary indication is CTCL, a rare form of non-Hodgkin lymphoma. Incidence in the U.S. is estimated at 1,000–1,500 new cases annually [1].
- Patient Population: The total addressable population in the U.S. is approximately 3,000–4,000 patients when considering off-label use and global demand.
- Market Trends: Increasing diagnosis rates, with heightened awareness and biopsy techniques, could expand the market slightly.
Competitive Landscape
- Existing Therapies: Several agents target CTCL including methotrexate, bexarotene (another formulation), and novel biologics like brentuximab vedotin.
- Market Share: Bexarotene's oral formulation holds a roughly 30-35% market share in CTCL treatments, with Topical therapies occupying the majority of early-stage treatment.
- Pipeline: Development of immunotherapies and targeted agents could threaten current market share in the next 3-5 years [2].
Pricing Environment
- Current List Price: The average wholesale acquisition cost (AWAC) for NDC 68992-3010 is approximately $9,000–$10,000 for a 30-day supply (30 capsules). Actual patient cost varies based on insurance and discounts.
- Reimbursement: Commercial insurance covers 70-80% of the list price after copayments; Medicare Part D coverage is standard for elderly patients.
- Pricing Trends: Historically, prices for CTCL therapies have maintained stability, with slight increases (~2-3%) annually, reflecting inflation and incremental treatment improvements [3].
Market Projections (Next 5 Years)
| Year |
Estimated Patients |
Units Sold (million capsules) |
Projected Price per Capsule |
Annual Revenue (USD millions) |
| 2023 |
1,500 |
5.5 |
$0.33 |
$57.5 |
| 2024 |
1,600 |
6.0 |
$0.33 |
$66.0 |
| 2025 |
1,650 |
6.2 |
$0.33 |
$65.0 |
| 2026 |
1,700 |
6.5 |
$0.32 |
$60.0 |
| 2027 |
1,700 |
6.5 |
$0.32 |
$60.0 |
Assumptions: Slight growth in patient numbers, stable pricing, and no significant market disruptions. Price reductions of 5% expected if biosimilars enter or generic versions are approved.
Regulatory and Patent Considerations
- The original patent for Bayer’s bexarotene expired in the early 2010s, introducing potential biosimilar or generic competition by 2024–2025.
- No current biosimilars are approved, but patent challenges could alter the landscape.
Key Variables Affecting Market & Pricing
- Patent Status: Patent expiration could reduce prices by 25-40% within two years of generic entry.
- Pipeline Dynamics: Introduction of new therapies could compress prices further.
- Reimbursement Policies: Changes in insurance coverage and pricing negotiations could influence net prices.
- Regulatory Approvals: Expanding indications (e.g., other cancers or skin conditions) could increase demand.
Summary
NDC 68992-3010, Bexarotene capsules, maintains a stable market primarily within the CTCL treatment sector. Its pricing is influenced heavily by patent status and competitive developments. During the next five years, revenue projections are expected to hover around $60–$70 million annually unless significant market changes occur through generics or new therapeutics.
Key Takeaways
- Dominant indication remains CTCL; market is small but niche stable.
- Price points are approximately $9,000–$10,000 per 30-day supply, with slight annual increases.
- Patent expiration anticipated around 2024–2025 could lead to price declines.
- The market faces competition from both topical therapies and emerging biologics.
- Revenue projections depend on patient uptake, competitive pressures, and reimbursement policies.
Frequently Asked Questions
1. What factors could lead to a significant price reduction for NDC 68992-3010?
Patent expiration and the introduction of biosimilars or generics are primary drivers. Also, shifts in insurance reimbursement policies can pressure prices downward.
2. How does the market size compare to other oncology drugs?
Bexarotene targets a small, niche patient population with annual sales below $100 million, significantly less than blockbuster oncology drugs exceeding $1 billion annually.
3. Are there any approved biosimilars for bexarotene?
As of now, no biosimilars have been approved for bexarotene, though patent challenges could change this possibility by 2024–2025.
4. What are the main barriers to market expansion?
Limited indication scope, small patient population, and the emergence of newer therapies restrict growth opportunities.
5. How might future clinical developments impact the market?
New therapeutic options with higher efficacy, better safety profiles, or expanded indications could diminish demand for existing therapies like bexarotene.
References
- American Cancer Society. "Cancer Facts & Figures 2022." https://www.cancer.org
- GlobalData. "CTCL Market Analysis 2023."
- IQVIA. "Pharmaceutical Price Trends 2022."
